PD633 - PREDOMINANT FAT MASS LOSS WITH PRESERVED FUNCTIONAL STATUS DURING TIRZEPATIDE TREATMENT AFTER PARTIAL PANCREATECTOMY FOR PANCREATIC NEOPLASM: A BODY COMPOSITION-GUIDED CASE REPORT
PD633
PREDOMINANT FAT MASS LOSS WITH PRESERVED FUNCTIONAL STATUS DURING TIRZEPATIDE TREATMENT AFTER PARTIAL PANCREATECTOMY FOR PANCREATIC NEOPLASM: A BODY COMPOSITION-GUIDED CASE REPORT
P. P. Dal Bello1,*
1Division of Clinical Nutrition, Department of Gastroenterology, Hospital das Clínicas, University of São Paulo, HCFMUSP, São Paulo, Brazil
Rationale: Obesity frequently coexists with pancreatic neoplasms and may persist after surgical treatment, but post-pancreatectomy weight management is challenging because excessive weight loss and muscle depletion may worsen nutritional and functional status. We report a body composition-guided nutritional follow-up of a woman with pancreatic neoplasm in follow-up after partial pancreatectomy who started tirzepatide for obesity management.
Methods: This is a longitudinal case report of a 64-year-old woman with obesity, under follow-up for pancreatic cancer. Clinical data, handgrip strength, body weight, body mass index, skeletal muscle mass, body fat mass, percent body fat, skeletal muscle index were collected from serial consultations and bioimpedance assessments. Tirzepatide was started at 2.5 mg weekly and increased to 5 mg weekly.
Results: Baseline weight was 96.1 kg, body mass index 33.65 kg/m², body fat mass 47.7 kg, percent body fat 49.7%, skeletal muscle mass 26.7 kg and skeletal muscle index 8.1 kg/m². Weight decreased to 92.0 kg (October 2025), 88.4 kg (January 2026) and 86.6 kg (March 2026). Body fat mass decreased to 39.7 kg and percent body fat to 45.9%, while skeletal muscle mass showed a modest reduction to 25.7 kg and skeletal muscle index to 7.6 kg/m². Handgrip strength remained stable at 20 kg. No nutritional deficiencies were observed. The patient received whey protein 30 g/day and β-hydroxy-β-methylbutyrate 3 g/day. Clinically, she reported improved disposition, no relevant adverse effects and only occasional constipation.
Conclusion: Tirzepatide was associated with clinically meaningful weight loss predominantly driven by fat mass reduction, with preservation of muscle function. Body composition monitoring may support safe obesity management in selected patients after pancreatic cancer.
Disclosure of Interest: None declared